Evommune Shares Rally 70% on Positive Phase IIa Eczema Trial
Evommune’s shares jumped 70% after its Phase IIa eczema candidate met primary endpoints, demonstrating favorable safety and efficacy signals in patients. Investors have rapidly revalued the stock on prospects for a pivotal Phase III launch and potential licensing interest.
1. Phase IIa Eczema Trial Success
Evommune announced that its Phase IIa study of the eczema therapy candidate met all primary endpoints, showing significant improvements in key clinical measures while maintaining a clean safety profile. This breakthrough result spurred a 70% surge in the company’s share price as the market reevaluated its valuation ahead of anticipated Phase III initiation.
Related News
NVDA
Nvidia Posts 85% Revenue Surge to $81.6B, Forecasts $91B Next Quarter
NVDA•
PII
Polaris Launches $9,999 RANGER 500 and Installs 8,000 m² Solar Array
PII•
AMZN
AWS Faces Challenge as Nvidia Forecasts $91B Q3 Sales, Musk Eyes 2028 Space Data Centers
AMZN•
LIVE
Live Ventures Inc Reports 14.8% Retail Growth, 3.8% Revenue Decline, $2.4M Loss
LIVE•
BLTE
Belite Bio Begins FDA NDA Rolling Submission, Q1 Loss Widens on $15.7M R&D
BLTE•
Sources
F